CORRECTION published: 29 March 2022 doi: 10.3389/fmed.2022.888928 Frontiers in Medicine | www.frontiersin.org 1 March 2022 | Volume 9 | Article 888928Edited and reviewed by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France *Correspondence: Bhushan Patwardhan bpatwardhan@gmail.com Specialty section: This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine Received: 03 March 2022 Accepted: 09 March 2022 Published: 29 March 2022 Citation: Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao BCS, Yadav B, Srikanth N and Patwardhan B (2022) Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol.Front.Med.9:888928.
doi: 10.3389/fmed.2022.888928Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol Arvind Chopra1, Preeti Chavan-Gautam2, Girish Tillu2, Manjit Saluja1, Swapnil Borse2, Sanjeev Sarmukaddam1, Susmita Chaudhuri3, BCS Rao4, Babita Yadav4, Narayanam Srikanth4and Bhushan Patwardhan2* 1Center for Rheumatic Diseases, Pune, India,2Center for Complementary and Integrative Health, Interdisci plinary School of Health Sciences, Savitribai Phule Pune University, Pune, In dia,3Translational Health Science and Technology Institute (THSTI), Faridabad, India,4Central Council for Research in Ayurvedic Science, New Delh i, India Keywords: COVID-19, immunogenicity, Withania somnifera , vaccine, Ayurveda, Ashwagandha, immunoadjuvant ACorrigendumon Randomized, Double Blind, Placebo Controlled, Clinical Trial t o Study Ashwagandha AdministrationinParticipantsVaccinatedAgainstCOVID-19onS afety,Immunogenicity,and ProtectionWithCOVID-19Vaccine–AStudyProtocol by Chopra, A., Chavan-Gautam, P., Tillu, G., Saluja, M., Bor se, S., Sarmukaddam, S., Chaudhuri, S., Rao, B.
C. S., Yadav, B., Srikanth, N., and Patwardhan, B.(2022).Front.Med.9:761655.doi:10.3389/fmed.2022.761655 In the original article, there was an error in the sentence “O ne tablet of Ashwagandha or placebo willbeadministeredtwicedaily(onemptystomachinthemorn ingandafterdinner)withwater.” Thecorrectionhasbeenmadetothe Eligibility section,“TrialIntervention ”subsectionandthe correctedsentenceappearsbelow: “One tablet of Ashwagandha or placebo will be administered dai ly (on empty stomach in the morning)withwater.” Theauthorsapologizeforthiserrorandstatethatthisdoesno tchangethescientiﬁcconclusions ofthearticleinanyway.Theoriginalarticlehasbeenupdate d.Publisher’sNote: All claims expressed in this article are solely those of the authors and d o not necessarily represent those of their aﬃliated organizations, or those of the publisher, the ed itors and the reviewers.
Any product that may be evaluated in thisarticle,orclaimthatmaybemadebyitsmanufacturer,isnotgua ranteedorendorsedbythepublisher. Copyright © 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, S armukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan.This is an open-access article distributed und er the terms of the Creative Commons Attribution License (CC BY).The use, distribution or reproduction in other forums is perm itted, provided the original author(s) and the copyright own er(s) are credited and that the original publication in this journ al is cited, in accordance with accepted academic practice.No use, distributionorreproductionispermittedwhichdoesnotco mplywiththeseterms.
